In CRC, SELENOP can serve as a potential therapeutic target, and intervention can be achieved by blocking the SELENOP‐LRP5/6 interaction via heparin; low expression in HCC is positively correlated with advanced staging and hypoxia scores (Prabhu 2023; Razaghi and Björnstedt 2024). Here, SELENOP is linked to hepatocellular carcinoma.